Sunshine Heart (CHFS) Upgraded to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Sunshine Heart (NASDAQ:CHFS) from a hold rating to a buy rating in a report published on Wednesday. The firm currently has $4.25 price target on the stock.
According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “
Separately, ValuEngine downgraded shares of Sunshine Heart from a sell rating to a strong sell rating in a report on Monday, October 2nd.
Sunshine Heart (NASDAQ:CHFS) opened at $3.43 on Wednesday. Sunshine Heart has a fifty-two week low of $2.87 and a fifty-two week high of $576.00.
In other Sunshine Heart news, major shareholder Ki Yong Choi purchased 78,211 shares of the business’s stock in a transaction that occurred on Wednesday, September 13th. The shares were bought at an average price of $0.64 per share, for a total transaction of $50,055.04. Following the acquisition, the insider now owns 1,731,464 shares in the company, valued at $1,108,136.96. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.00% of the stock is currently owned by corporate insiders.
WARNING: “Sunshine Heart (CHFS) Upgraded to “Buy” at Zacks Investment Research” was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/12/10/sunshine-heart-chfs-upgraded-to-buy-at-zacks-investment-research.html.
Sunshine Heart Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. It focused on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunshine Heart Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Heart Inc and related companies with MarketBeat.com's FREE daily email newsletter.